Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (41-50 of 246) with videos related to

Pageof 25
Sort By:
International Journal of Molecular Sciences|July 4, 2019
Cardiodynamic Interactions between Two S1P<sub>1</sub> Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate EffectsPierre-Eric Juif, Mike Ufer, Jasper Dingemanse
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Validated LC-MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic studyElke Spieker, Winfried Wagner-Redeker, Jasper Dingemanse
Journal of Clinical Pharmacology|August 28, 2007
Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthasePaul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|April 6, 2017
Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy SubjectsMilena Issac, Jasper Dingemanse, Patricia N Sidharta
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 26, 2012
Miglustat effects on the basal nasal potential differences in cystic fibrosisAnissa Leonard, Patrick Lebecque, Jasper Dingemanse, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2013
Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral dosesDaniela Baldoni, Marcelo Gutierrez, Wolfgang Timmer, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 15, 2020
Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjectsJasper Dingemanse, Pascal Charef, Jed Black, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825Jasper Dingemanse, Laurent B Nicolas, Luc van Bortel
Clinical Pharmacology and Therapeutics|September 16, 2017
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P<sub>1</sub> Receptor Modulator PonesimodDominik Lott, Thorsten Lehr, Jasper Dingemanse, et al.
Basic & Clinical Pharmacology & Toxicology|November 4, 2015
Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor ModulatorNicolas Guérard, Christian Zwingelstein, Matthias Hoch, et al.
Pageof 25

Showing results (41-50 of 246) with videos related to

Sort By:
Pageof 25
International Journal of Molecular Sciences|July 4, 2019
Cardiodynamic Interactions between Two S1P<sub>1</sub> Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate EffectsPierre-Eric Juif, Mike Ufer, Jasper Dingemanse
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2011
Validated LC-MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic studyElke Spieker, Winfried Wagner-Redeker, Jasper Dingemanse
Journal of Clinical Pharmacology|August 28, 2007
Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthasePaul L M van Giersbergen, Jasper Dingemanse
Journal of Clinical Pharmacology|April 6, 2017
Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy SubjectsMilena Issac, Jasper Dingemanse, Patricia N Sidharta
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 26, 2012
Miglustat effects on the basal nasal potential differences in cystic fibrosisAnissa Leonard, Patrick Lebecque, Jasper Dingemanse, et al.
The Journal of Antimicrobial Chemotherapy|October 10, 2013
Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral dosesDaniela Baldoni, Marcelo Gutierrez, Wolfgang Timmer, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 15, 2020
Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjectsJasper Dingemanse, Pascal Charef, Jed Black, et al.
Clinical Pharmacology in Drug Development|April 29, 2016
Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825Jasper Dingemanse, Laurent B Nicolas, Luc van Bortel
Clinical Pharmacology and Therapeutics|September 16, 2017
Modeling Tolerance Development for the Effect on Heart Rate of the Selective S1P<sub>1</sub> Receptor Modulator PonesimodDominik Lott, Thorsten Lehr, Jasper Dingemanse, et al.
Basic & Clinical Pharmacology & Toxicology|November 4, 2015
Effect of Hepatic or Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Ponesimod, a Selective S1P1 Receptor ModulatorNicolas Guérard, Christian Zwingelstein, Matthias Hoch, et al.
Pageof 25